Gut Microbiota-Based Therapies for Irritable Bowel Syndrome

Area of Science:

• Gastroenterology
• Microbiome research
• Pharmacology

Background:

• Irritable bowel syndrome (IBS) is a prevalent gastrointestinal disorder with complex, multifactorial causes.
• Potential IBS triggers include gut microbiota dysbiosis, altered visceral sensitivity, and genetic/environmental factors.
• Systemic antibiotics may disrupt gut homeostasis, potentially increasing IBS risk.

Purpose of the Study:

• To review current and emerging therapeutic strategies for IBS targeting the gut microbiota.
• To highlight interventions aimed at restoring gut microbial balance and improving IBS symptoms.

Main Methods:

• Review of literature on IBS pathogenesis and therapeutic interventions.
• Focus on treatments modulating the gut microbiota, including antibiotics, medical foods, prebiotics, probiotics, and dietary changes.
• Discussion of SYN-010, a novel statin formulation for constipation-predominant IBS.

Main Results:

• Several interventions, including rifaximin and serum-derived bovine immunoglobulin, are used for IBS with diarrhea by targeting gut microbiota.
• SYN-010 shows promise in reducing methane production by Methanobrevibacter smithii, a factor in constipation-predominant IBS.
• These approaches aim to re-establish a healthy gut microbiome.

Conclusions:

• Modulating the gut microbiota is a key strategy in managing IBS.
• Emerging therapies like SYN-010 offer new avenues for treating specific IBS subtypes.
• Restoring gut microbial balance holds potential for symptom amelioration in IBS patients.